海外の治験の状況「膀胱がん」での検索結果
31件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A comparative study of MPDL3280A versus chemotherapy in patients with advanced bladder cancer.
- Advanced tumor and metastastic disease MedDRA version: 19.1 Level: LLT Classification code 10046721 Term: Urothelial carcinoma bladder stage III System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States
- 2014-11-04
Authorised
- A Phase 3 trial of BCG with or without pembrolizumab for high risk non-muscle invasive bladder cancer (KEYNOTE-676)
- High-risk Non-muscle Invasive Bladder Cancer (NMIBC) MedDRA version: 20.0 Level: LLT Classification code 10022877 Term: Invasive bladder cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Finland, Germany, Greece, Italy, Korea, Republic of, Malaysia, Netherlands, Norway, Peru, Poland, Portugal, Spain, Turkey, United Kingdom, United States
- 2018-09-24
Authorised
- A Phase 3 trial of BCG with or without pembrolizumab for high risk non-muscle invasive bladder cancer (KEYNOTE-676)
- High-risk Non-muscle Invasive Bladder Cancer (NMIBC) MedDRA version: 20.0 Level: LLT Classification code 10022877 Term: Invasive bladder cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Finland, Germany, Greece, Italy, Korea, Republic of, Malaysia, Netherlands, Norway, Peru, Poland, Portugal, Spain, Turkey, United Kingdom, United States
- 2018-09-14
Authorised
- Pembrolizumab (MK-3475) in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
- Non-Muscle Invasive Bladder Cancer (NMIBC) MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, Finland, France, Greece, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Sweden, Turkey, United Kingdom, United States
- 2015-11-27
Not recruiting
- Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
- Bladder Cancer;Transitional Cell Cancer of the Renal Pelvis and Ureter;Urethral Cancer
- Brazil, Canada, Finland, Netherlands, New Zealand, Norway, South Africa, United Kingdom
- 1999-11-01
Authorised
- Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Advanced Urothelial Bladder Cancer
- Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Bulgaria, Canada, China, Czech Republic, Hungary, Israel, Italy, Japan, Korea, Republic of, Philippines, Poland, Russian Federation, Spain, Taiwan, Thailand, Turkey, United States, Vietnam
- 2018-11-23
Recruiting
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
- High-risk Non-muscle Invasive Bladder Cancer
- Australia, Austria, Belgium, Canada, Finland, Germany, Korea, Republic of, Malaysia, Norway, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, United States
- 2018-10-15
Authorised
- Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Advanced Urothelial Bladder Cancer
- Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Bulgaria, Canada, China, Czech Republic, Hungary, Israel, Italy, Japan, Korea, Republic of, Philippines, Poland, Russian Federation, Spain, Taiwan, Thailand, Turkey, United States, Vietnam
- 2018-08-15
Recruiting
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
- Bladder Cancer;Bladder Tumors;Neoplasms, Bladder
- Argentina, Brazil, Canada, Chile, China, France, Hong Kong, Italy, Mexico, Netherlands, Russian Federation, Spain, Turkey, United Kingdom, United States
- 2018-04-17
Not recruiting
- A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
- Bladder Cancer
- Brazil, Canada, Netherlands, Singapore
- 2019-10-31
